Scancell Holdings plc (SCLP.L)
- Previous Close
9.60 - Open
9.36 - Bid 9.40 x --
- Ask 9.80 x --
- Day's Range
9.36 - 9.50 - 52 Week Range
7.59 - 18.29 - Volume
148,854 - Avg. Volume
395,936 - Market Cap (intraday)
89.182M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.01 - Earnings Date Jan 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.73
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
www.scancell.co.ukRecent News: SCLP.L
Performance Overview: SCLP.L
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCLP.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCLP.L
Valuation Measures
Market Cap
89.18M
Enterprise Value
95.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.26
Price/Book (mrq)
--
Enterprise Value/Revenue
21.17
Enterprise Value/EBITDA
-9.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.22%
Return on Equity (ttm)
-269.84%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.53M
Diluted EPS (ttm)
-0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
13.08M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.97M
Research Analysis: SCLP.L
Company Insights: SCLP.L
SCLP.L does not have Company Insights